Evercore ISI Group Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $134

Benzinga · 08/03 15:03
Evercore ISI Group analyst Gavin Clark-Gartner maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from $120 to $134.